Sernova Corp
XTSX:SVA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Sernova Corp
Additional Paid In Capital
Sernova Corp
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sernova Corp
XTSX:SVA
|
Additional Paid In Capital
CA$8.4m
|
CAGR 3-Years
26%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Additional Paid In Capital
$111.3m
|
CAGR 3-Years
9%
|
CAGR 5-Years
23%
|
CAGR 10-Years
22%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Additional Paid In Capital
$228.2m
|
CAGR 3-Years
17%
|
CAGR 5-Years
38%
|
CAGR 10-Years
21%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Additional Paid In Capital
CA$28.5m
|
CAGR 3-Years
17%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Additional Paid In Capital
$27.3m
|
CAGR 3-Years
53%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Sernova Corp
Glance View
Sernova Corp. is a clinical stage regenerative medicine company. The company is headquartered in London, Ontario. The firm is engaged in the development of its Cell Pouch and associated technologies, including therapeutic cells for the treatment of chronic diseases and local immune protection technologies. The company is focused on developing a treatment for insulin-dependent human diabetes and other metabolic, blood and neurological diseases with therapeutic cells placed into its implanted and prevascularized medical device, protected from immune system attack. The Cell Pouch is designed to create a microvessel rich, tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the treatment of chronic diseases, such as diabetes and thyroid disease. Its lead program is the clinical development of the Cell Pouch for treatment of patients with insulin dependent diabetes. The company is also evaluating Cell Pouch for the treatment of patients with hemophilia A.
See Also
What is Sernova Corp's Additional Paid In Capital?
Additional Paid In Capital
8.4m
CAD
Based on the financial report for Jan 31, 2022, Sernova Corp's Additional Paid In Capital amounts to 8.4m CAD.
What is Sernova Corp's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
17%
Over the last year, the Additional Paid In Capital growth was 49%. The average annual Additional Paid In Capital growth rates for Sernova Corp have been 26% over the past three years , 17% over the past five years .
